Safety profile of aromatase inhibitors combined with CDK4/6 inhibitors: a real-world analysis based on FAERS
Abstract Background The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) is now a cornerstone first-line treatment. However, the comprehensive safety profile of this combination has not been fully characterized. The aim of this study was to evaluate the real-world safety profile of...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
SpringerOpen
2026-05-01
|
| Ráidu: | Future Journal of Pharmaceutical Sciences |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s43094-026-00989-6 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|